^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G12V

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients (NCT03190941)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    09/21/2017
    Primary completion :
    06/29/2027
    Completion :
    06/29/2028
    KRAS • ALK • NRAS • HRAS
    |
    KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous
    A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) (NCT05846516)
    Phase 1
    Amal Therapeutics
    Recruiting
    Last update posted :
    06/03/2024
    Initiation :
    03/13/2023
    Primary completion :
    12/01/2026
    Completion :
    03/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154
    A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers (NCT05786924)
    Phase 1
    Black Diamond Therapeutics, Inc.
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    04/18/2023
    Primary completion :
    06/01/2026
    Completion :
    12/01/2026
    KRAS • BRAF • NRAS
    |
    KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D
    |
    S241656
    DC Vaccine in Pancreatic Cancer (NCT03592888)
    Phase 1
    University of Pennsylvania
    Completed
    Last update posted :
    05/07/2024
    Initiation :
    11/20/2018
    Primary completion :
    02/12/2024
    Completion :
    02/12/2024
    KRAS • HLA-A
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) (NCT05726864)
    Phase 1/2
    Elicio Therapeutics
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    04/14/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    KRAS • NRAS
    |
    KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V
    |
    ELI-002 7P
    CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (NCT05631899)
    Phase 1
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    04/03/2023
    Primary completion :
    12/30/2025
    Completion :
    12/30/2026
    KRAS
    |
    PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
    |
    Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC
    KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC (NCT05254184)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    01/24/2024
    Initiation :
    11/01/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP-202) (NCT04620330)
    Phase 2
    Verastem, Inc.
    Completed
    Last update posted :
    01/12/2024
    Initiation :
    12/31/2020
    Primary completion :
    08/29/2023
    Completion :
    12/12/2023
    KRAS • BRAF
    |
    KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)
    Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer (NCT04146298)
    Phase 1/2
    Changhai Hospital
    Recruiting
    Last update posted :
    09/01/2023
    Initiation :
    10/21/2021
    Primary completion :
    12/01/2024
    Completion :
    03/01/2025
    KRAS • NRAS • HRAS
    |
    KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    TCR-T Cell Therapy on Advanced Pancreatic Cancer (NCT05438667)
    Phase 1
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Recruiting
    Last update posted :
    07/18/2023
    Initiation :
    06/07/2022
    Primary completion :
    06/30/2025
    Completion :
    05/30/2026
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12
    |
    cyclophosphamide
    Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation (NCT05173805)
    Phase 1/2
    Shanghai YingLi Pharmaceutical Co. Ltd.
    Enrolling by invitation
    Last update posted :
    07/18/2023
    Initiation :
    01/30/2022
    Primary completion :
    04/30/2024
    Completion :
    12/30/2024
    PD-L1 • KRAS • MSI • PD-1
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
    |
    YL-15293
    Phase I Trial of Defactinib and VS-6766. (FRAME) (NCT03875820)
    Phase 1
    Institute of Cancer Research, United Kingdom
    Active, not recruiting
    Last update posted :
    07/10/2023
    Initiation :
    12/12/2017
    Primary completion :
    04/30/2023
    Completion :
    10/31/2023
    KRAS • RAS
    |
    KRAS mutation • KRAS G12V • RAS mutation • KRAS G12
    |
    Avmapki (avutometinib) • Fakzynja (defactinib)